MedPath

Prevention of in-stent neointimal proliferation by Pioglitazone Study

Not Applicable
Completed
Conditions
Type 2 diabetic patients with ischemic heart disease
Registration Number
JPRN-UMIN000000485
Lead Sponsor
Bell Land General Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

(1).Severe liver or renal insufficiency(2).TIMI-flow grade <= 2 (3).Cardiogenic shock or congestive heart failure (4).Contraindication to antiplatelet therapy (5).Patient with gastrointestinal bleeding or transient ischemic attack (6).Ineligible for CABG (7). Ineligible for percutaneous coronary intervention

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Angiographical restenosis and target lesion revascularization at 6 months follow-up
Secondary Outcome Measures
NameTimeMethod
eointimal volume assessed by intravascular ultrasound at 6months follow-up
© Copyright 2025. All Rights Reserved by MedPath